France Liquid Biopsy Market (2025-2030)
The France Liquid Biopsy Market was valued at $74.6 Million in 2025 and projected to reach to $129.2 Million by 2030, representing a compound annual growth rate of 11.6%. France's liquid biopsy market is poised for sustained expansion, driven by increasing healthcare investments in precision medicine and early disease detection.
France Liquid Biopsy Market Trends and Insights
- This expansion reflects France's strong healthcare infrastructure and increasing adoption of non-invasive diagnostic technologies across oncology and other clinical applications.
- France is positioning itself as a key market within Europe, driven by rising demand for early cancer detection and personalized medicine solutions. The French market benefits from substantial investment in healthcare innovation and favorable regulatory frameworks that support the commercialization of advanced diagnostic platforms.
- Between 2025 and 2030, France is expected to witness accelerated market penetration as healthcare providers and patients increasingly recognize the clinical and economic advantages of liquid biopsy testing.
- France's growing emphasis on precision medicine and preventive healthcare is fueling this momentum. France's liquid biopsy sector is characterized by increasing collaboration between diagnostic companies, research institutions, and healthcare systems.
- The market's 11.6% compound annual growth rate underscores France's commitment to modernizing its diagnostic capabilities and improving patient outcomes through cutting-edge molecular testing technologies..
Key Market Statistics
- CAGR (2025-2030) 11.6% CAGR
- Market Size, 2025 ~USD 74.6 Million
- Forecast, 2030 ~USD 129.2 Million
- Country France
France Liquid Biopsy Market Overview
Market Valuation Growth :
France's liquid biopsy market is valued at $74.6 million in 2025, with a projected CAGR of 11.6% through 2030, reaching $129.2 million. This growth trajectory demonstrates strong market momentum in non-invasive diagnostic adoption across French healthcare institutions.
European Leadership Position :
France is establishing itself as a key liquid biopsy hub within Europe, leveraging its advanced healthcare infrastructure and regulatory framework. The country's commitment to precision medicine and early cancer detection is driving accelerated market penetration and clinical adoption rates.
Healthcare Infrastructure Advantage :
France's robust healthcare system, including universal coverage and well-established diagnostic networks, provides an ideal environment for liquid biopsy integration. Public and private healthcare providers are increasingly incorporating these technologies into standard oncology and preventive care protocols.
Non-Invasive Diagnostic Adoption :
Rising clinical acceptance of liquid biopsy for cancer screening, monitoring, and treatment selection is accelerating across French hospitals and diagnostic centers. Growing patient preference for non-invasive testing methods is further propelling market expansion in oncology and emerging therapeutic areas.
France Liquid Biopsy Market Dynamics
- The country's strong regulatory environment and reimbursement policies are facilitating broader adoption of liquid biopsy technologies across oncology departments and diagnostic laboratories.
- With a 11.6% CAGR through 2030, France is becoming an attractive market for both established diagnostics companies and innovative biotech firms seeking European market entry. The French market benefits from collaborative relationships between academic medical centers, pharmaceutical companies, and diagnostic providers.
- Government initiatives supporting personalized medicine and cancer prevention programs are expected to accelerate clinical implementation.
- As awareness among French physicians and patients grows regarding the benefits of early detection and non-invasive monitoring, market penetration will continue to strengthen, positioning France as a significant contributor to European liquid biopsy market growth..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Qiagen N.V.
- Agilent Technologies, Inc.
- Danaher Corporation
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- France's liquid biopsy market is valued at $74.6 million in 2025 and is forecast to reach $129.2 million by 2030, representing a 11.6% CAGR.
- France's strong healthcare infrastructure and regulatory environment are accelerating the adoption of non-invasive diagnostic technologies across clinical settings.
- Early cancer detection and personalized medicine initiatives are primary growth drivers in France's liquid biopsy market.
- France is emerging as a significant European hub for liquid biopsy innovation, supported by collaborative partnerships between diagnostic companies and healthcare institutions.
Liquid Biopsy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CIRCULATING TUMOR DNA (Circulating Biomarker Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 11.8% from 2025 to 2030 |
| Largest Segment | BLOOD (Sample Type) |
| Market Size Base Year (Billions) | ~USD 4.04 (2025) |
| Revenue Forecast (Billions) | ~USD 7.05 (2030) |
| Segments Covered | Product & Service, Circulating Biomarker Type, Technology, Application, Type, Clinical Application, Sample Type, End User |
France Liquid Biopsy Market Report Segmentation
8 segment dimensions are covered across the global market.
By Product & Service
- Assay Kits
- Instruments
- Services
By Circulating Biomarker Type
- Cell-Free Dna
- Circulating Tumor Cells
- Circulating Tumor Dna
- Extracellular Vesicles
- Other Circulating Biomarkers
By Technology
- Multi-Gene Parallel Analysis Using Ngs
- Single-Gene Analysis Using Pcr Microarrays
By Application
- Cancer Applications
- Non-Cancer Applications
By Type
- Breast Cancer
- Colorectal Cancer
- Infectious Disease Testing
- Lung Cancer
- Melanoma
- Non-Invasive Prenatal Testing
- Organ Transplantation
- Other Cancers
- Prostate Cancer
By Clinical Application
- Early Cancer Screening
- Recurrence Monitoring
- Therapy Selection
- Treatment Monitoring
By Sample Type
- Blood
- Other Sample Types
By End User
- Academic & Research Centers
- Hospitals & Physician Laboratories
- Hospitals & Physicians Laboratories
- Other End Users
- Reference Laboratories
Target Audience
- Diagnostic Companies & IVD Manufacturers : In vitro diagnostics firms and liquid biopsy solution providers need France-specific market data to assess commercial viability, identify distribution partnerships, and develop localized go-to-market strategies for European expansion.
- Pharmaceutical & Biotech Companies : Pharma organizations developing companion diagnostics and precision oncology solutions require detailed French market insights to support clinical trial planning, regulatory submissions, and commercial launch strategies in this key European market.
- Healthcare Investors & Private Equity : Investment firms evaluating opportunities in French diagnostics and precision medicine need comprehensive market sizing, growth projections, and competitive analysis to inform investment decisions and portfolio company valuations.
- Hospital Networks & Diagnostic Centers : French healthcare institutions and laboratory networks require market intelligence on liquid biopsy adoption trends, clinical evidence, and reimbursement policies to guide technology procurement and service expansion decisions.
- Healthcare Consultants & Strategy Advisors : Management consulting firms and healthcare advisors supporting clients in France need authoritative market data and trend analysis to develop strategic recommendations for diagnostics adoption, competitive positioning, and market opportunity assessment.
Key Companies in the France Liquid Biopsy Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SANOFI | France | Public Company | Vaccines (pediatric, hexavalent, travel and epidemic),Immunology & Inflammation,Rare Diseases & Neurology, |
| CONMED CORPORATION | United States | Public Company | Orthopedic sports medicine and power tools (BioBrace, Y-Knot, Hall, related disposables),General surgery and minimally invasive platforms (AirSeal, Buffalo Filter, endomechanical, electrosurgery),Endoscopic technologies and patient monitoring (GI therapeutics, ECG/EEG, defibrillation pads), |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, markers, localization, treatment),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa ProVu, CoolSeal), |
| UNITED IMAGING HEALTHCARE CO., LTD. | China | Public Company | Magnetic Resonance Imaging,Computed Tomography,Molecular Imaging (PET/CT, SPECT), |
| NATERA, INC. | United States | Public Company | Oncology MRD and CGP (Signatera, Latitude, Altera, Empower oncology use),Women’s health (Panorama, Horizon, Fetal Focus, Vistara, Anora),Transplant and nephrology (Prospera, Renasight), |
| GUARDANT HEALTH | United States | Public Company | Guardant360 liquid portfolio (CDx and Guardant360 Liquid),Guardant Reveal and minimal residual disease testing,Guardant360 Tissue and tissue-based profiling, |
| MYRIAD GENETICS, INC. | United States | Public Company | Hereditary and Companion Diagnostics (MyRisk, BRACAnalysis CDx, MyChoice CDx),Oncology Prognostics and Tumor Profiling (Prolaris, EndoPredict, Precise Tumor),Women’s Health and Prenatal (Prequel, Foresight, SneakPeek, FirstGene), |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Arrays and genotyping products, |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual and reproductive health assays, |
| EXACT SCIENCES CORPORATION | United States | Private Company | Cologuard and Cologuard Plus,Oncotype DX breast and colon tests,Hereditary and risk assessment tests (Riskguard, Cancerguard, Genetic Testing), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| GRAIL, INC. | United States | Public Company | Galleri multi-cancer early detection screening,Diagnostic aid for suspected cancer,Precision oncology and MRD/monitoring (RUO methylation platform), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Life Science segment,Clinical Diagnostics segment, |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation analyzers and reagents,Urinalysis, blood gas/electrolyte, and related analyzers, |
| MDXHEALTH | Belgium | Public Company | Confirm mdx (prostate cancer tissue test),ExoD (non-invasive urine prostate cancer test),Genomic Prostate Score collaboration, |
| PERSONALIS, INC. | United States | Public Company | Pharma and biopharma research services (ImmunoID NeXT, exome/transcriptome projects),MRD and clinical liquid biopsy (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling and Dx (NeXT Dx and related tests), |
SANOFI
Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees, operating as a public company in the healthcare and drug development sector.
CONMED CORPORATION
CONMED Corporation is a U.S.-based public company founded in 1970 with 3,900 employees that manufactures and distributes medical devices and equipment.
HOLOGIC, INC.
Hologic, Inc. is a private U.S. company founded in 1985 with 7,070 employees focused on diagnostic and surgical medical devices.
UNITED IMAGING HEALTHCARE CO., LTD.
United Imaging Healthcare Co., Ltd. is a Chinese public company founded in 2011 with 8,703 employees specializing in medical imaging equipment and solutions.
NATERA, INC.
Natera, Inc. is a U.S. public company founded in 2003 with 6,138 employees providing genetic testing and cell-free DNA analysis services.
GUARDANT HEALTH
Guardant Health is a U.S. public company founded in 2011 with 2,498 employees focused on liquid biopsy and genomic testing for cancer detection.
MYRIAD GENETICS, INC.
Myriad Genetics, Inc. is a U.S. public company founded in 1991 with 2,700 employees specializing in genetic testing and personalized medicine.
ILLUMINA, INC.
Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees that develops and manufactures DNA sequencing and genetic analysis systems.
QIAGEN N.V.
QIAGEN N.V. is a Dutch public company founded in 1984 with 5,500 employees providing molecular diagnostics and life sciences research tools.
EXACT SCIENCES CORPORATION
Exact Sciences Corporation is a U.S. private company founded in 1995 with 7,150 employees specializing in molecular diagnostics and cancer screening.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a U.S. public company founded in 1956 with 125,000 employees providing laboratory equipment, reagents, and analytical services.
GRAIL, INC.
GRAIL, Inc. is a U.S. public company founded in 2015 with 910 employees focused on early cancer detection through blood-based genomic testing.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a U.S. public company founded in 1952 with 7,450 employees manufacturing clinical diagnostics and life science research products.
SYSMEX CORPORATION
Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees specializing in in vitro diagnostics and hematology analyzers.
MDXHEALTH
MDxHealth is a Belgian public company founded in 2003 with 364 employees providing molecular diagnostics and epigenetic testing services.
PERSONALIS, INC.
Personalis, Inc. is a U.S. public company founded in 2011 with 260 employees offering whole genome sequencing and cancer genomics analysis.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for France ($74.6M in 2025) with verified CAGR projections through 2030. Validate investment decisions and revenue forecasts with country-specific market intelligence and competitive positioning analysis.
- Regulatory & Reimbursement Insights : Understand France's unique healthcare reimbursement landscape, regulatory pathways, and clinical adoption barriers. Gain actionable intelligence on navigating French healthcare systems and optimizing market entry strategies for liquid biopsy solutions.
- Competitive Landscape Analysis : Identify key market players, emerging competitors, and partnership opportunities specific to the French liquid biopsy ecosystem. Benchmark your positioning against established diagnostics providers and innovative startups operating in France.
- Clinical Application Opportunities : Discover high-growth clinical segments within France including oncology, cardiovascular disease monitoring, and emerging therapeutic areas. Understand physician adoption patterns and patient demand drivers across French healthcare institutions.
- Strategic Market Entry Planning : Develop data-driven market entry strategies tailored to France's healthcare infrastructure, stakeholder networks, and growth catalysts. Leverage country-specific insights to prioritize resource allocation and maximize market penetration timelines.
Frequently asked questions
What is the current size of France's liquid biopsy market?
France's liquid biopsy market is valued at $74.6 million in 2025 and is expected to grow to $129.2 million by 2030.
What is the projected growth rate for France's liquid biopsy market?
France's liquid biopsy market is projected to grow at a compound annual growth rate (CAGR) of 11.6% from 2025 to 2030.
What are the main drivers of growth in France's liquid biopsy market?
Key growth drivers in France include increasing demand for early cancer detection, adoption of personalized medicine, strong healthcare infrastructure, and favorable regulatory frameworks supporting diagnostic innovation.
How does France's liquid biopsy market compare to other European markets?
France represents a significant market within Europe, with robust growth driven by healthcare investment, regulatory support, and clinical adoption of non-invasive diagnostic technologies.
What clinical applications are driving France's liquid biopsy market expansion?
Oncology applications, particularly early cancer detection and monitoring, are the primary clinical drivers, supported by growing interest in precision medicine and preventive healthcare in France.
RESEARCH METHODOLOGY
The study involved estimating activities to determine the current size of the liquid biopsy market. Exhaustive secondary research was done to collect information on the liquid biopsy industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the liquid biopsy market.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| QIAGEN | Sales Manager |
| F. Hoffmann-La Roche Ltd. | Sales Executive |
Market Size Estimation
Liquid biopsy is a non-invasive method for diagnosing and monitoring diseases. Blood or other body fluids are collected to analyze cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or circulating tumor cells (CTCs).
Data Triangulation
After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand & supply sides.
Market Definition
Both top-down and bottom-up approaches were used to estimate and validate the liquid biopsy market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- Primary and secondary research have determined the revenues of leading players operating in the liquid biopsy market.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Stakeholders
- Manufacturers & Distributors of Liquid Biopsy Products
- Hospitals & Diagnostic Centers
- Reference Laboratories
- R&D Companies
- Research Laboratories and Academic Institutes
- Liquid Biopsy Service Providers
- Government Associations
- Venture Capitalists & Investors
Report Objectives
- To define, describe, segment, and forecast the liquid biopsy market, by product & service, circulating biomarker type, technology, application, clinical application, sample type, end user, and region
- To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and challenges)
- To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as acquisitions, collaborations, partnerships, agreements, and product launches & approvals in the liquid biopsy market
- To benchmark players within the liquid biopsy market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
Get the Full Liquid Biopsy Market Report
Full forecast, segment splits, and company analysis for all Liquid Biopsy Market.
- US Liquid Biopsy Market
- Canada Liquid Biopsy Market
- Germany Liquid Biopsy Market
- UK Liquid Biopsy Market
- Italy Liquid Biopsy Market
- Spain Liquid Biopsy Market
- China Liquid Biopsy Market
- Japan Liquid Biopsy Market
- India Liquid Biopsy Market
- Brazil Liquid Biopsy Market
- Mexico Liquid Biopsy Market
- Rest Of Europe Liquid Biopsy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report